Table 3.

Results of the multivariable linear regression analyses for change in remnant cholesterol when LDL was derived by 3 different methodologies.

Friedewald Equation	B	Beta	P Value
Age	–0.21	–0.10	0.708
Female	8.79	0.18	0.074
Diabetes	–5.25	–0.10	0.278
ASCVD	0.87	0.01	0.913
Statin	–2.45	–0.04	0.669
Alirocumab 75mg vs evolocumab 140mg	–8.39	–0.14	0.156
Alirocumab 150mg vs evolocumab 140mg	–12.09	–0.21	0.036
Triglyceride group (high vs low)	–20.06	–0.41	<0.001
Direct Measurement
Age	–0.31	–0.14	0.193
Female	8.39	0.16	0.113
Diabetes	–1.61	–0.03	0.757
ASCVD	2.90	0.04	0.734
Statin	–8.60	–0.14	0.165
Alirocumab 75mg vs evolocumab 140mg	–1.56	–0.03	0.806
Alirocumab 150mg vs evolocumab 140mg	–7.29	–0.12	0.236
Triglyceride group (high vs low)	–16.29	–0.32	0.001
Martin/Hopkins Method
Age	–0.27	–0.14	0.185
Female	8.62	0.19	0.053
Diabetes	–4.16	–0.09	0.342
ASCVD	1.15	0.02	0.872
Statin	–0.87	–0.02	0.866
Alirocumab 75mg vs evolocumab 140mg	–6.04	–0.11	0.259
Alirocumab 150mg vs evolocumab 140mg	–12.76	–0.24	0.015
Triglyceride group (high vs low)	–16.76	–0.38	<0.001

ASCVD = atherosclerotic cardiovascular disease.